Introduction
STATs (signal transducers and activators of transcription) are members of a recently identi®ed family of transcription factors that activate gene transcription in response to a number of dierent cytokines (for review see Hoey and Grusby, 1999; Leonard and O'Shea, 1998; O'Shea, 1997) . The STATs are latent cytoplasmic proteins that are promptly activated by tyrosine phosphorylation by the cytokine receptor associated JAK (Janus) kinases after cytokine exposure. STAT phosphorylation allows the dimerization of individual STAT proteins via their SH2 (src homology 2) domains. The resulting functional STAT dimer is then capable of migrating directly to the nucleus where it can bind DNA and directly activate cytokine responsive gene transcription. To date seven dierent STAT proteins have been described each activated by speci®c cytokine/cytokine receptor combinations.
In this review, we will focus on two STAT proteins, Stat6 and Stat4, which are activated speci®cally by IL-4 and IL-12, respectively. Both of these STATs have been found to be critical for the function and development of T helper cells. We will discuss the speci®c characteristics that set Stat6 and Stat4 apart from the other STAT proteins, how Stat6 and Stat4 are activated and regulated as well as the regulation of potential target genes by Stat6 and Stat4. We will also discuss the respective roles of Stat6 and Stat4 in the generation of a productive immune response.
Structural characteristics of Stat6
IL-4 is a cytokine that can aect the proliferation, viability, gene expression and dierentiation of lymphocytes (for review see Paul, 1997) . Early work on IL-4 signal transduction suggested that IL-4 signaling would parallel the general STAT pathway described above (Kohler and Rieber, 1993; Kotanides and Reich, 1993; Schindler et al., 1994) . For example, IL-4, like other cytokines, had been found to induce rapid and speci®c gene activation events within hours of cytokine stimulation. Additionally there was evidence that a latent cytoplasmic factor was tyrosine phosphorylated after IL-4 stimulation and subsequently redistributed to the nucleus. In order to clone the factor, an IL-4 responsive DNA element from the FcgRI promoter was used to purify this activity from protein extracts derived from an IL-4 treated cell line (Hou et al., 1994) . The protein that bound to the site was tyrosine phosphorylated in response to IL-4 and shared homology with other known STAT proteins in its proposed DNA binding, SH3 and SH2 domains. The protein was termed by several groups STF-IL-4, IL-4 STAT, IL-4 NAF and ultimately Stat6 (Hou et al., 1994; Kotanides and Reich, 1993; Quelle et al., 1995; Schindler et al., 1994) .
Although much of the structure-function analysis of STAT proteins has been performed with Stat1 as the prototype, Stat6 and Stat4 share a number of the functional domains characteristic of STAT proteins, such as a central DNA-binding domain, a conserved SH2 domain for dimerization, an SH3 domain and a C-terminal transactivation domain (Hoey and Grusby, 1999; Leonard and O'Shea, 1998; O'Shea, 1997) . The NH2-terminal 130 amino acids are conserved among STAT family members and this region is essential for tetramerization of dimerized STAT molecules, which enables cooperative DNA binding on the promoters containing multiple potential STAT recognition sites (Vinkemeier et al., 1998; Xu et al., 1996) .
Like other STAT proteins, Stat6 must be tyrosine phosphorylated by JAK kinases in order for dimerization via the STAT SH2 domains and subsequent nuclear translocation to occur. The speci®c tyrosine on Stat6 that is phosphorylated has been mapped to Y-641, just C-terminal of the SH2 domain (Mikita et al., 1996) . Additionally, other residues surrounding the Y-641 were shown to be capable of in¯uencing dimer formation in vivo (Mikita et al., 1998a) . Recently, a conditionally active form of Stat6 was generated by fusing Stat6 with a form of the estrogen receptor (ER) (Kamogawa et al., 1998; Kurata et al., 1999) . In the presence of an estrogen analog, the Stat6-ER chimera eciently dimerized and translocated to the nucleus to activate transcription. This occurred in the absence of IL-4 stimulation and tyrosine phosphorylation of the Stat6-ER protein, suggesting that when dimerization is achieved by other means, the phospho-tyrosine is dispensable and does not aect the subsequent events of nuclear translocation and transcriptional activation.
Experiments using deletion mutants and GAL4 DNA binding domain fusions of Stat6 have also revealed a potent transactivation domain in the C terminus of the Stat6 protein (Lu et al., 1997; Mikita et al., 1996; Moriggl et al., 1997) . This region is rich in prolines, similar to transactivation domains of other transcription factors. Interestingly the Stat6 activation domain bears very little sequence similarity to the activation domains of other STAT proteins. One study indicated that the eectiveness of the Stat6 activation domain itself could be increased by IL-4 stimulation, suggesting an additional post-translational modi®ca-tion of this region mediated by IL-4 (Moriggl et al., 1997) . Other STAT proteins have been shown to be phosphorylated on speci®c serine residues and this modi®cation can in¯uence their activation capabilities (Wen et al., 1995) . Thus far though, no evidence exists that Stat6 is modi®ed in this manner although the notion certainly deserves further attention.
Stat6 can also exist in dierent isoforms depending on the tissue or cell type studied. Two naturally occurring isoforms (Stat6b and Stat6c) of human Stat6 appear to arise from alternate splicing of the Stat6 mRNA (Patel et al., 1998) . The Stat6b isoform has a deletion at the amino terminus of the full length Stat6 protein while Stat6c lacks a portion of the SH2 domain. Both of these isoforms can attenuate various IL-4 responses when overexpressed. The Stat6c isoform in particular behaves eectively as a dominant negative to Stat6 by reducing Stat6 tyrosine phosphorylation, dampening IL-4 induced mitogenesis, and blocking the upregulation of IL-4 inducible genes. Stat6c appears to function as a dominant negative by blocking the dimer formation of endogenous Stat6. Another form of a truncated Stat6 was recently shown to be coexpressed with native Stat6 speci®cally in mast cells (Sherman et al., 1999) . The origin of the truncated form (alternative splicing of mRNA or proteolysis of the native protein) is not clear, but it appears to lack the carboxy terminal portion of conventional Stat6. The mast cell speci®c isoform binds avidly to the Stat6 DNA binding site but its role functionally is not clear at this time. Based on these observations it appears that an additional level of Stat6 regulation could be asserted by the presence or absence of these functionally distinct isoforms expressed in various tissues.
Although IL-4, and the similar cytokine IL-13, is the primary activator of Stat6, there are a few reports of other stimuli that can result in Stat6 activation. In primary B lymphocytes both Ig and CD40 crosslinking can induce Stat6 tyrosine phosphorylation (Karras et al., 1996 (Karras et al., , 1997 . In the case of Ig crosslinking, there appears to be an additional dependence on PKC to mediate this signal (Karras et al., 1996) . In rat cardiac myocytes, angiotensin II was shown to be able to induce Stat6 phosphorylation and nuclear translocation (Mascareno et al., 1998) . PDGF was also able to activate Stat6 in NIH3T3 cells and the addition of IL-4 could potentiate this eect (Patel et al., 1996) . Additionally, leptin was able to activate several STAT proteins, including Stat6, through the long form of the ob receptor transfected into COS cells (Ghilardi et al., 1996) . It is unclear at this point what role Stat6 is playing in these alternative pathways, and experiments using Stat6-de®cient mice have not yet revealed a clear biological role for these observations.
Transcriptional regulation by Stat6
IL-4 is the primary cytokine that can activate Stat6 and additionally, IL-4 activates the expression of a very speci®c gene program that regulates the viability, proliferation and dierentiation of the responding cell. This precise speci®city is controlled at two levels. First, the STAT proteins bind via their SH2 domains to speci®c docking sites on the corresponding activated cytokine receptor (Hou et al., 1994; Mikita et al., 1998a; Schindler et al., 1995) . For example, Stat6 only recognizes phosphorylated tyrosines on the cytoplasmic tail of IL-4 receptor a chain and does not interact with the phospho-tyrosines on the IFNg receptor. Conversely, Stat1, which is activated by IFN signaling, does not recognize a phospho-peptide derived from the IL-4 receptor (Schindler et al., 1995) . Therefore a part of the speci®c cytokine response is controlled at the level of the STAT/cytokine receptor interaction. Additionally, while a number of the STAT proteins recognize very similar DNA binding sites in the promoters of cytokine responsive genes, Stat6 stands out as having a unique binding site preference. Most of the STAT proteins recognize an IFNg Activating Sequence (GAS), originally identi®ed as a high anity Stat1 binding site. This site consists of a palindromic sequence separated by a 3 bp spacer (TTCNNNG-AA)(N3 site). Stat6 is also able to bind the GAS site but only at a low anity (Schindler et al., 1995) . Stat6 instead displays a much greater preference for a site with a 4 bp spacer (TTCNNNNGAA)(N4 site) (Schindler et al., 1995) . None of the other STAT proteins tested are capable of recognizing the N4 site in vitro (Mikita et al., 1996) . Indeed, most of the Stat6 binding sites mapped in IL-4 responsive promoters have consisted of N4 sites (Delphin and Stavnezer, 1995; Kotanides and Reich, 1996) . Therefore, Stat6 is able to selectively regulate IL-4 signal transduction not only by speci®cally interacting with the IL-4 receptor but also by recognizing a unique subset of STAT binding sites.
In order to understand mechanistically how Stat6 induces gene expression in response to IL-4, a great deal of eort has been focused on the analysis of the promoters of IL-4 inducible genes. The best characterized thus far is the promoter for the IL-4 induced Ig germline transcript for the Ce gene. In the Ce promoter, an IL-4 response region (IL4RR) had been mapped by transient transfection and reporter assays (Delphin and Stavnezer, 1995) . Within the IL4RR is an N4 Stat6 site and this site is required for the IL-4 responsiveness of the promoter. Interestingly, unlike other STAT proteins, Stat6 is unable to transactivate this site when it is removed from its promoter context, even though Stat6 is still capable of binding the site in vitro (Mikita et al., 1996) . Directly adjacent to the Ce Stat6 site is a binding site for a C/EBP transcription factor (Delphin & Stavnezer, 1995) . C/EBP consists of a family of nuclear factors that are constitutively expressed and not induced by IL-4. When the Stat6 site is now combined with the C/EBP site, IL-4 induced reporter gene activity is restored (Mikita et al., 1996) . This functional synergy between Stat6 and C/EBP is dependent on the transactivation domains of both factors although no evidence exists that Stat6 and C/ EBP directly interact (Mikita et al., 1998b) . Additionally, the presence of C/EBP on the promoter fragment appears to be able to reduce the dissociation rate of Stat6 bound to the IL4RR and this may help explain the functional synergy observed in the reporter assays (Mikita et al., 1998b) .
The Ce promoter is also activated in B cells that are stimulated through CD40, a surface molecule on B cells that receives signals of T cell help. CD40 induces the activation of NFkB family members and NFkB sites were also mapped within the IL4RR (Berberich et al., 1994; Delphin and Stavnezer, 1995) . Functional studies indicated that optimal IL-4 induction of the Ce promoter required intact Stat6 and NFkB sites and these sites also activated transcription synergistically (Delphin and Stavnezer, 1995; Iciek et al., 1997; Messner et al., 1997) . Unlike the situation with C/ EBP, it has been recently demonstrated by coimmunoprecipitation and GST pulldown studies that NFkB family members and Stat6 can physically interact and bind cooperatively to the IL4RR (Shen and Stavnezer, 1998) . The presence of NFkB proteins appears to increase the anity of Stat6 to the IL4RR which could in part explain the functional synergy. Moreover, the p50 NFkB family member, which does not have its own transactivation domain, was able to augment the transactivation potential of Stat6 when the two were complexed together on the binding site (Shen and Stavnezer, 1998) . Functional NFkB binding sites have also been mapped near Stat6 sites in the promoters of other IL-4 inducible genes including CD23 and the human Sg3 gene (Richards and Katz, 1994; Schaer et al., 1999) . From the studies on the Ce promoter it can be concluded that Stat6 has an acute dependence on the presence of other transcription factors in an IL-4 responsive promoter. Only with the proper combination of these factors does IL-4 induced transcription occur in a physiological manner.
Stat6 and the IL-4 receptor
Stat6 is activated primarily via the ligation of the IL4 receptor (IL-4R) (for review see Nelms et al., 1999) . The IL-4R is composed of two chains, the 140 kD a chain (IL-4Ra) which has high anity for IL-4 and the common g chain which is shared among a number of hematopoietic cytokine receptors. The homodimerization of IL-4Ra itself is capable of leading to Stat6 activation in cultured cells, but the most likely physiological stimulus is through a combination of the a and g chains. The JAK kinases, Jak 1 and 3, are able to bind the a and g chains respectively and are responsible for the subsequent phosphorylation of the IL-4 receptor itself as well as of Stat6.
IL-13, a cytokine secreted by activated T cells, is also capable of activating Stat6 under some circumstances and shares many of the biological properties of IL-4 (Kohler et al., 1994; Zurawski and de Vries, 1994) . The overlapping functional and biochemical activities of IL-4 and IL-13 can be explained by the fact that their receptors share the IL-4Ra chain (Lin et al., 1995; Zurawski et al., 1995) . Unlike IL-4, the IL-4Ra chain is unable to recognize IL-13 by itself, but when combined with the IL-13Ra chain the complex binds IL-13 with a high anity (Aman et al., 1996; Hilton et al., 1996) .
The IL-4Ra chain is tyrosine phosphorylated on ®ve tyrosine residues, providing potential binding sites for SH2 and PTB domain proteins, and a great deal of eort has been expended to elucidate the importance of these sites in IL-4 signaling (Smerz-Bertling and Duschl, 1995) . Receptor mutagenesis and cell transfection studies have suggested that the tyrosines can be functionally subdivided into two categories: a gene activation domain and a growth domain (Keegan et al., 1994; Ryan et al., 1996) . The amino acids 437 ± 557 that contain one of the phosphotyrosines appear to be important for providing a growth signal to transfected cells after IL-4 stimulation, and amino acids 575 ± 657 which include three of the phosphotyrosines transmit signals that stimulate IL-4 induced gene expression. Additionally, it was demonstrated that Stat6 activation correlated with the phosphorylated tyrosines in the gene regulation domain while the phosphorylation and activation of the large adaptor molecule, IRS-2, corresponded to the growth domain (Keegan et al., 1994) . From these studies it was concluded that signals generated through Stat6 would activate a gene program induced by IL-4 while IRS-2 would mediate the mitogenic signal through the activation of various downstream regulators such as PI3 kinase.
Stat6-deficient mice
Studies of mice made de®cient for Stat6 by homologous recombination in ES cells supported the notion that the Stat6 pathway provided the gene activation signal in response to IL-4 stimulation. Indeed, lymphocytes from Stat6-de®cient mice were unable to upregulate MHC Class II, CD23, and IL-4Ra expression in response to IL-4, supporting the importance of Stat6 in the activation of IL-4 inducible genes (Kaplan et al., 1996a; Shimoda et al., 1996; Takeda et al., 1996b) . Stat6 de®cient B lymphocytes were also unable to switch to the immunoglobulin isotypes IgG1 and IgE in response to IL-4, a ®nding that correlated with an inability to transcribe the corresponding germline transcripts for these genes (Linehan et al., 1998) . Changes in gene expression in B cells and macrophages after IL-13 stimulation were also demonstrated to be defective in Stat6-de®cient mice supporting the notion that Stat6 activation is also an important downstream eector of IL-13 signaling (Takeda et al., 1996a) . Stat6-de®cient T helper cells were also unable to dierentiate into Th2 cells in vitro or in vivo, an observation that will be discussed further below (Kaplan et al., 1996a; Shimoda et al., 1996; Takeda et al., 1996b) .
Stat6 and cellular proliferation
One surprising ®nding that came out of the studies on the Stat6-de®cient mice was that Stat6-de®cient lymphocytes did not proliferate to IL-4 as well as wildtype controls (Kaplan et al., 1996a; Shimoda et al., 1996; Takeda et al., 1996b) . This is in spite of the fact that IRS-2 was shown to be activated normally by IL-4 in the Stat6-de®cient lymphocytes (Kaplan et al., 1998a) . This observation is in con¯ict with the in vitro work discussed above that suggested that Stat6 did not play a role in proliferation but was only involved in gene activation. The proliferation defect in the Stat6-de®cient cells was determined to be due to a block in the progression from the G1 to S phase of the cell cycle (Kaplan et al., 1998a) . The disregulation of the cdk inhibitor, p27kip, after IL-4 stimulation in Stat6-de®cient cells has been implicated in the cell cycle block (Kaplan et al., 1998a) . Under normal circumstances p27kip protein levels are decreased in IL-4 stimulated cells, relieving the inhibition on the cell cycle dependent kinases. In the absence of Stat6, p27kip levels remain high for an extended period of time after IL-4 stimulation but are reduced normally in response to other cytokines, such as IL-2, which activates Stat5. This defect in p27kip expression does not appear to be due to a direct transcriptional eect of Stat6 on the p27kip gene since p27kip message levels are normal in Stat6-de®cient lymphocytes. Instead, Stat6 is probably activating another regulator(s) that modulates the expression levels of cell cycle regulators.
The notion that Stat6 may be an important regulator of mitogenesis when cells respond normally to IL-4 leads to the question of whether or not inappropriate activation of Stat6 could also be involved in uncontrolled cell growth in an oncogenic state. There are a few examples of constitutive Stat6 activation in transformed cell lines. For example, one of the products of the Philadelphia chromosome translocation, p190 BCR/ABL , is capable of inducing prominent Stat6 activation in the absence of cytokine (Ilaria and Van Etten, 1996) . Additionally, HTLV-1 transformed T cells also constitutively activate the JAK/Stat6 pathway (Takemoto et al., 1997) . These are of course only correlative observations, and a direct role for Stat6 in cellular transformation has not yet been demonstrated.
Negative regulation of Stat6 activity
A great deal has been discovered about Stat6 activation in response to IL-4, but now eorts are underway to understand how the activity of Stat6 is modulated or turned o. A recently identi®ed family of proteins, suppressor of cytokine signaling (SOCS or SSI or JAB), is believed to regulate the JAK/STAT pathway by interfering with the function of the JAK kinases (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . Overexpression of one family member, SOCS1, in a murine B cell line resulted in decreased Jak1 phosphorylation, decreased Stat6 phosphorylation and inhibition of IL-4 induced CD23 expression (Losman et al., 1999) . SOCS mRNA is induced by the cytokines themselves and SOCS1 expression in particular can be induced by IL-4 in some cell types (Naka et al., 1997; Starr et al., 1997) . This leads to a model where IL-4 signaling via Stat6 initially occurs unopposed but is subsequently dampened by a negative feedback mechanism through the IL-4/Stat6 dependent induction of SOCS1 expression. This is supported by the observation that Stat6 phosphorylation is prolonged in SOCS1-de®cient lymphocytes (Naka et al., 1998; Starr et al., 1998) . SOCS proteins therefore may be important regulators for the termination of an immune or cytokine response.
IFNg has also been shown to be a negative regulator of Stat6 dependent transcription of target genes. Recently the IFNg dependent inhibition was shown to require Stat1 activation (Venkataraman et al., 1999) . IFNg treatment reduced Stat6 phosphorylation, DNA binding and transactivation after IL-4 stimulation. The inhibitory eects of IFNg were not apparent immediately but required several hours of IFNg treatment suggesting a requirement for de novo protein synthesis of a Stat1 target gene (Venkataraman et al., 1999) . SOCS1 expression, in particular, is also induced by IFNg and its induction after pretreatment has been proposed to explain the negative regulation of IFNg on IL-4 signal transduction.
Bcl-6 is another negative regulator of Stat6 activity. Bcl-6 is a transcriptional repressor normally expressed in germinal center B cells and some T cells (Cattoretti et al., 1995; Seyfert et al., 1996) . Although Bcl-6 does not resemble Stat6 structurally, Bcl-6 is capable of recognizing the Stat6-speci®c DNA binding site (Dent et al., 1997) . When Bcl-6 is overexpressed it can block the ability of Stat6 to transactivate the CD23 promoter by presumably competing for the Stat6 binding site (Dent et al., 1997) . These in vitro observations are supported by the in vivo observations made in Bcl-6-de®cient mice (Dent et al., 1997) . Bcl-6-de®cient mice are characterized by a Th2 in¯ammatory disease of the heart and lungs. Moreover, T cells from Bcl-6-de®cient mice predominantly express Th2 cytokines. These results suggest that in the absence of Bcl-6, Stat6 may be activating transcription in an unregulated manner resulting in an overactive Th2 response. Therefore, Bcl-6 normally may play an important role in regulating Stat6 activity and modulating a Th2 immune response. Interestingly, in mice made de®cient for both Stat6 and Bcl-6, the Th2 in¯ammatory disease and cytokine production still develop revealing an additional Stat6-independent pathway for Th2 dierentiation in vivo (Dent et al., 1998) .
Stat4
Stat4 was ®rst isolated by two groups using degenerative-PCR or low-stringency hybridization, both of which were based on homology with the SH2 domain of other STAT proteins (Yamamoto et al., 1994; Zhong et al., 1994) . To date, most studies of Stat4 have been focused on the functional analysis of this molecule in T cells, because Stat4 is mainly phosphorylated by IL-12-mediated signaling pathway in T cells. Here we will ®rst describe the signal transduction pathway of IL-12 brie¯y, and then discuss the role of Stat4 in the functional dierentiation and proliferation of T cells.
Stat4 expression is restricted in myeloid cells, thymus and testis (Zhong et al., 1994) . In human T cells, Stat4 expression is dramatically induced by activation with PHA (phytohemaglutinin), although its expression is very low in resting T cells (Bacon et al., 1995) . IL-12 is the major cytokine that can activate Stat4, resulting in its tyrosine phosphorylation, in both human and mouse (Leonard and O'Shea, 1998) . The IL-12 receptor is composed of two chains, termed IL-12Rb1 and IL12Rb2, and ligand binding results in heterodimer formation and activation of the receptor associated JAK kinases, Jak2 and Tyk2 (Sinigaglia et al., 1999) .
Stat4 is phosphorylated by these tyrosine kinases, homodimerizes via its SH2 domain, and translocates into nucleus where it can recognize traditional N3 STAT target sequences in IL-12 responsive genes (Bacon et al., 1995; Cho et al., 1996; Jacobson et al., 1995) .
Although IL-12 appears to be the predominant activator of Stat4, Stat4 can also be phosphorylated in response to IFN-g stimulation through activation of Jak1 and Tyk2, but this has only been observed in human cells (Cho et al., 1996) . Additionally, recent studies in human vascular smooth muscle and endothelial cells demonstrated that the urokinase-type plasminogen activator (uPA) receptor is associated with Jak1 and Tyk2, and uPA stimulation of these cells resulted in Stat4 phosphorylation (Dumler et al., 1999) . IL-17 can also activate Stat4 in human monocytic leukemia cell lines (Subramaniam et al., 1999) . Furthermore, IL-2 can induce Jak2 and Stat4 activation in NK cells but not in T cells (Wang et al., 1999) .
IL-12 is capable of inducing a mitogenic response in some cell types. A role for Stat4 in transducing this signal was demonstrated in Stat4-de®cient mice (Kaplan et al., 1996b) . Stat4-de®cient lymphocytes were speci®cally defective in their ability to proliferate in response to IL-12. Additionally, Stat-4-de®cient lymphocytes, like Stat6-de®cient lymphocytes, were unable to downregulate p27kip protein levels after cytokine stimulation (Kaplan et al., 1998a) . These data suggest that STAT proteins, as a general mechanism, may control cytokine-mediated cell proliferation by regulating the expression of cell cycle inhibitors which are critically involved in cell cycle progression.
T helper cell differentiation

CD4
+ T helper lymphocytes dierentiate into two distinct subsets, de®ned by their unique cytokine pro®les and distinct functional abilities. T helper 1 (Th1) cells produce IL-2 and IFNg, whereas Th2 cells secrete IL-4, IL-5, IL-6 and IL-13 (for review see Abbas et al., 1996; O'Garra, 1998) . Th1 cells are responsible for cell-mediated/in¯ammatory immunity and can enhance defenses against infectious agents and cancer, while Th2 cells are essential for humoral immunity and the clearance of parasitic antigens. Tumor immunity is often mediated by cytotoxic T lymphocytes whose activation is supported by Th1 cytokines. However, the unbalanced Th1/Th2 response can result in pathological conditions. For example, a polarized Th1 response can cause in¯ammatory or autoimmune diseases such as fulminant hepatitis, insulin-dependent diabetes mellitus, ulcerative colitis and graft-versus host diseases. In contrast, an exaggerated Th2 response can lead to allergic diseases such as atopic dermatitis and bronchial asthma (Andre et al., 1996; de Pater-Huijsen et al., 1997; Kapsenberg et al., 1991; Kuchroo et al., 1995; Racke et al., 1994) .
The most potent factors that can promote Th1 and Th2 dierentiation are the cytokines IL-12 and IL-4 respectively (Abbas et al., 1996; O'Garra, 1998) . This has been clearly demonstrated in mice de®cient for the cytokines themselves or their receptor subunits. For example, mice de®cient for IL-12 or IL-12Rb1 chain are unable to generate Th1 cells, and mice lacking IL-4 or the IL-4Ra chain are de®cient for Th2 responses (Kopf et al., 1993; Kuhn et al., 1991; Magram et al., 1996; Noben-Trauth et al., 1997; Wu et al., 1997) .
Stat4 and T helper cell differentiation
Although Stat4 is expressed both in Th1 and Th2 cells, Stat4 can only be phosphorylated by IL-12 in Th1 cells due to the downregulation of IL-12Rb speci®cally in Th2 cells (Szabo et al., 1997) . This suggested that Stat4 plays an important role in Th1 cell function or development. In fact, mice lacking Stat4 clearly demonstrated that Stat4 is necessary for the generation of Th1 cells (Kaplan et al., 1996b; Thierfelder et al., 1996) . Lymphocytes from Stat4-de®cient mice were unable to make high levels of IFNg, characteristic of Th1 cells, after IL-12 priming. Additionally, NK cell cytolytic functions were severely impaired in Stat4 knockout mice. Moreover, abrogation of Stat4 signaling in a murine diabetes model signi®cantly reduced the development of CD4 + T cell-dependent diabetes, but not CD4 + T cell-independent diabetes (Holz et al., 1999) . These data highlight the importance of Stat4 and Th1 responses in pathogenesis of autoimmune diseases, and provide exciting therapeutic options to treat these diseases.
However, little is known about the exact mechanism by which Stat4 activation leads to Th1 dierentiation, including the target genes of Stat4. Recently, one of the potential target genes of Stat4, termed ERM, was identi®ed (Ouyang et al., 1999) . ERM is a transcription factor that belongs to the Ets family of transcription factors. The expression of ERM is speci®cally induced by IL-12 in wild-type Th1 cells, but not in Stat4-de®cient T cells. However, the role of this factor in Th1 dierentiation is still unknown. The IFN-inducible factor-1 (IRF-1) is also considered to be a Stat4 target gene, since Stat4 can bind to and transactivate the IRF-1 promoter (Galon et al., 1999) . Interestingly IRF-1-de®cient mice were defective in their Th1 responses. It is unclear at this point whether or not the defect is intrinsic to the T cells though, since antigen presenting cells from IRF-1-de®cient mice do not function normally as well (Loho et al., 1997; Taki et al., 1997) .
Stat4 is expressed in both CD4 + T cells and CD8 + T cells, both of which can produce IFN-g, although these cells have distinct functions. A recent report showed that the requirement for Stat4 is dierent in these cells. Only CD4 + cells require Stat4 for IFN-g production after the cells are activated through the T cell receptor, while Stat4 is required in both lineages for IL-12-mediated IFN-g production (Carter and Murphy, 1999) .
Stat6 and T helper cell differentiation
The IL-4 dependent aspect of Th2 dierentiation also appears to require the activation of Stat6 (Kaplan et al., 1996a; Shimoda et al., 1996; Takeda et al., 1996b) . Stat6-de®cient T lymphocytes are unable to dierentiate into IL-4 producing Th2 eector cells when cultured with antigen and IL-4 in vitro or when stimulated by a Th2 inducing antigen (anti-IgD) in vivo. Additionally, Stat6-de®cient animals are unable to mount an immune response to helminthic parasites and therefore are unable to clear the parasitic infections (Kaplan et al., 1998b) . IL-4 signaling and Stat6 appear to play an important role in the development of an allergic asthma response as well. In a murine asthma model, Stat6-de®cient mice did not develop airway hyperresponsiveness after allergen sensitization like their wildtype littermates and were protected from allergic asthma (Akimoto et al., 1998; Kuperman et al., 1998) . Clearly, the ability to modulate the activation of the Stat6 pathway by pharmacological means could be eective for directing the immune response from pathological to protective.
The molecular mechanisms of how Stat6 promotes Th2 dierentiation are unclear as of now. Several developmentally regulated transcription factors, such as GATA-3 and c-maf, have been shown to be critical for the generation of IL-4 producing Th2 cells (Ho et al., 1996; Kim et al., 1999; Zheng and Flavell, 1997) . The expression of these transcription factors is induced as Th precursor cells become Th2 eectors. Interestingly, the induction of GATA-3 expression in Th2 cells has been shown to be dependent on IL-4 stimulated Stat6 activation, although it is unclear whether or not Stat6 activates GATA-3 transcription directly (Ouyang et al., 1998) . Ectopic expression of activated Stat6 in Th1 cells can also result in the expression of GATA-3 and c-maf in these cells (Kurata et al., 1999) . Additionally, a recent report demonstrated that large scale chromatin remodeling of the IL-4 gene occurs as cells dierentiate into Th2 eectors (Agarwal and Rao, 1998) . This process was also shown to be Stat6 dependent. Once again, it is unclear whether or not Stat6 is directly responsible for the chromatin remodeling or instead is activating a subset of genes, including downstream eectors like GATA-3 and c-maf, that could be responsible for the chromatin changes at the IL-4 locus. The identi®cation and characterization of Stat6 target genes in dierentiating Th2 cells would greatly aid in answering these questions.
Th1 cell differentiation in the absence of Stat4 and Stat6
It had been clearly demonstrated in the Stat4 and Stat6-de®cient mice that these transcription factors play important roles in Th1 and Th2 dierentiation, respectively. Interestingly, mice made de®cient for both Stat4 and Stat6 (double-de®cient) revealed a STATindependent pathway for Th1 development (Kaplan et al., 1998c) . Lymphocytes from double-de®cient mice were unable to generate IL-4 producing Th2 cells like their Stat6-de®cient littermates, supporting the notion that Stat6 is critical for the dierentiation of Th2 cells. Interestingly, double-de®cient lymphocytes were capable of generating IFNg producing Th1 cells, unlike the Stat4-de®cient lymphocytes. The double-de®cient lymphocytes produce signi®cantly more IFNg than the Stat4-de®cient lymphocytes although the level is still approximately fourfold less than IL-12 stimulated wildtype Th1 cells. Using ELISPOT analysis, it was determined that the absolute number of IFNg producing cells was similar between the double-de®cient and the wildtype Th1 cultures but the amount of IFNg produced on a per cell basis was reduced in the cells that lacked both Stat4 and Stat6. These results suggest that Stat4 is not absolutely required for the generation of IFNg producing Th1 cells but is instead necessary for the upregulation of IFNg production from Th1 cells. This Stat4 independent pathway for Th1 cell development is revealed only in the absence of any Stat6 and Stat4 signaling.
Conclusions and future directions
The analysis of mice de®cient for Stat4 and Stat6 has provided a great deal of insight into the roles of these proteins in the regulation of an immune response (Figure 1 ). Still, a number of important issues remain to be resolved. Of primary importance is the identi®ca-tion of transcriptional targets for Stat4 and Stat6 in lymphocytes. The characterization of target genes would hopefully lead to a mechanistic understanding of how Stat4 and Stat6 aect cellular proliferation and dierentiation events. Additionally, it is also clear that the transcriptional potency of STATs is in¯uenced a great deal by their association with other proteins, either through direct interaction on a promoter (Stat6 and NFkB) or through post-translational modi®cation (serine phosphorylation of Stat1). Future experiments aimed at the identi®cation and characterization of Stat4 and Stat6 interacting partners could potentially reveal new mechanisms for STAT regulation. Regardless, the critical and exquisitely speci®c roles of Stat4 and Stat6 in T helper cell dierentiation suggest that these proteins would be ideal therapeutic targets for modulating an immune response.
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